search
Back to results

Genome Driven Primary Care Clinics - an RCT

Primary Purpose

Health Services Administration, Genetic Predisposition, Microbial Colonization

Status
Active
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Mutation arrays, NGS panels, GWAS, WES, WGS,
wearable monitors
Sponsored by
Carmel Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Health Services Administration focused on measuring wearable monitors, microbiome, genomic medicine,

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All clinic adult population
  • All diseases

Exclusion Criteria:

  • Mentality unable to understand and sign consent

Sites / Locations

  • Carmel Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Usual care

Arm Description

Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function

No intervention at all

Outcomes

Primary Outcome Measures

chronic diseases in clinic
whole clinic Incidence rate/100,000 of major chronic diseases (hypertension, Hyperlipidemia, DM, IHD, Cancer)
Mortality in clinic
whole clinic mortality rate/100,000 of major chronic diseases (DM, cancer, IHD)
costs in clinic
Total annual cost of clinic activity in NIS, including cost of diagnostic tests and hospitalization

Secondary Outcome Measures

Full Information

First Posted
February 14, 2021
Last Updated
February 28, 2021
Sponsor
Carmel Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04781205
Brief Title
Genome Driven Primary Care Clinics - an RCT
Official Title
Operating Community Primary Care Clinics Under Personalized Medicine Paradigm and Determining Differences in Health Outcomes Between Clinics With and Without Intervention.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Carmel Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A cluster randomized controlled study of 40 primary care clinics in Northern Israel (20 intervention clinics, 20 usual care clinics) to evaluate the value of introducing a precision medicine/genomic approach/paradigm on the clinical and economical outcomes of the clinics. Intervention includes 3 elements: 1. DNA extraction and evaluation (up to the level of WGS); 2. Feces sample for microbiome study, 3. Wearable devices for continuous monitoring of body functions. Expected number of participants is 100,000 in each arm. Results will be calculated for a clinic as a unit and not for individuals (each clinic to be compared to "twin" selected clinic).
Detailed Description
Study major aim: Assess whether employing a paradigm of genomic/precision medicine in primary care clinics can lead to an improvement in the medical or economic outcomes of the clinic as a unit. Specific and secondary aims Study differences in morbidity, mortality, quality of life or the cost of medical service indicators between clinics operating under a genome driven paradigm compared to usual care clinics. Examine whether the public has an interest in extensive genetic testing. Examine whether the medical staff has an interest and ability to assimilate a genomic approach in the routine clinic work. Identify links between genetic markers (mutations, variants) and different diseases (incidence or clinical behavior) or different drug responses (resistance, effectiveness, side-effects). Examine whether the implementation of prolonged personal monitoring devices will lead to improved morbidity and mortality indices. Examine whether measuring genomic variability in the microbiome has implications on health status or means of coping with different diseases and different health conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Health Services Administration, Genetic Predisposition, Microbial Colonization
Keywords
wearable monitors, microbiome, genomic medicine,

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Paired cluster randomization of 40 clinics into 20 intervention and 20 usual care. Randomization from among a couple of similar clinics
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
No intervention at all
Intervention Type
Genetic
Intervention Name(s)
Mutation arrays, NGS panels, GWAS, WES, WGS,
Intervention Description
DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
Intervention Type
Device
Intervention Name(s)
wearable monitors
Intervention Description
test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
Primary Outcome Measure Information:
Title
chronic diseases in clinic
Description
whole clinic Incidence rate/100,000 of major chronic diseases (hypertension, Hyperlipidemia, DM, IHD, Cancer)
Time Frame
5 years
Title
Mortality in clinic
Description
whole clinic mortality rate/100,000 of major chronic diseases (DM, cancer, IHD)
Time Frame
5 ytears
Title
costs in clinic
Description
Total annual cost of clinic activity in NIS, including cost of diagnostic tests and hospitalization
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All clinic adult population All diseases Exclusion Criteria: Mentality unable to understand and sign consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gad Rennert, MD, PhD
Organizational Affiliation
Clalit National Cancer Control Center Carmel Medical Center, Technion,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Carmel Medical Center
City
Haifa
ZIP/Postal Code
3436217
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
study comparative unit is a whole clinic and not an individual participants

Learn more about this trial

Genome Driven Primary Care Clinics - an RCT

We'll reach out to this number within 24 hrs